Meghann L. Smith

Meghann L. Smith

Auto-generated profile, based on publicly available information

Meghann L. Smith

Department of Perioperative Medicine, National Institutes of Health Clinical Center, NIH, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
SVSebastian Vogel
Sebastian Vogel
SKSayuri Kamimura
Sayuri Kamimura
TATaruna Arora
Taruna Arora
MSMeghann L. Smith
Meghann L. Smith
LALuis E.F. Almeida
Luis E.F. Almeida
ZQZena Quezado
Zena Quezado

2 November 2023 in Blood
Verified
Journal Article
Open access
LKLe Kang
Le Kang
ZQZena Quezado
Zena Quezado
SKSayuri Kamimura
Sayuri Kamimura
MSMeghann L. Smith
Meghann L. Smith
YTYuki Tahara
Yuki Tahara
STSwee Lay Thein
Swee Lay Thein
Disclosures. No relevant conflicts of interest to declare.Figure 1

27 January 2026 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
SVSebastian Vogel
Sebastian Vogel
SKSayuri Kamimura
Sayuri Kamimura
ENEric Nguyen
Eric Nguyen
MSMeghann Smith
Meghann Smith
LALuis E.F. Almeida
Luis E.F. Almeida
ZQZena Quezado
Zena Quezado
The platelet nucleotide-binding domain leucine-rich repeat-containing protein 3 (NLRP3) inflammasome is upregulated in sickle cell disease (SCD) and promotes platelet aggregation. We previously identified Bruton tyrosine kinase (BTK) as a critical regulator of the platelet NLRP3 inflammasome. However, whether NLRP3 contributes to platelet function beyond aggregation in SCD and whether these effects can be modulated through BTK inhibition, has been incompletely understood. Here, we show that platelet secretion, platelet spreading, platelet aggregation, and in vitro thrombus formation in response to collagen are elevated in SCD mice and are reduced following treatment of mice with the NLRP3 inhibitor MCC950 or the BTK inhibitor ibrutinib. The NLRP3 activator nigericin partially reversed the inhibitory effects of ibrutinib across all platelet function assays. Together, we identify the NLRP3 inflammasome as a critical mediator of platelet hyperreactivity in SCD mice, which can be targeted via BTK inhibition.